Board of Directors
Stuart J. M. Collinson, PhD, MBA Chairman
Dr. Collinson is a partner at Forward Ventures. Dr. Collinson is a director of Affinium Pharmaceuticals Inc., Asteres Inc., Sequel Pharmaceuticals Inc., Tioga Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals Inc. for $600 million). Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris Limited (acquired by Quadrant plc, now part of Elan Corporation PLC). He held senior management positions at GlaxoWellcome PLC (now GlaxoSmithKline PLC) and Baxter International Inc., and was a consultant with The Boston Consulting Group.
Albert Cha, MD, PhD
Dr. Cha is a managing partner with Vivo Ventures. He was an early investor in Aspreva Pharmaceuticals (NASDAQ: ASPV), CoTherix (CTRX), Biodel (BIOD), and Bioform Medical (BFRM). Other investments include Acura Pharmaceuticals (ACUR), AMAG Pharmaceuticals (AMAG), APT Pharmaceuticals, Avanir Pharmaceuticals (AVNR), Discovery Labs (DSCO), Repros Therapeutics (RPRX), and Tria Beauty. He currently serves on the board of several private biopharmaceutical and medical device companies. Dr. Cha has also served as founding or interim CEO for several portfolio companies. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting.
Jim Glasheen, PhD
Dr. Glasheen is a general partner with Technology Partners. He joined Technology Partners from CIT Venture Capital, where he served as Managing Director, leading the Group's efforts in Life Science investing. Previously, he was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Dr. Glasheen is on the Advisory Council of the Entrepreneurial Center at the University of California, Berkeley.
James Huang, MBA
Mr. Huang is a venture partner with Vivo Ventures. He has extensive operating and business development experience through 20 years of experience in the pharmaceutical industry. He joined Vivo from Anesiva, where he served as president and previously as senior vice president of business development and commercial operations. Prior to Anesiva, he was VP Business Development and Commercial Operations at Tularik Inc prior to its acquisition by Amgen. Mr. Huang was also a product director for diabetes at SmithKline Beecham PLC (now GlaxoSmithKline), and also held various positions in product development, business development, sales and marketing, and research and development at SmithKline Beecham, Bristol-Myers Squibb, and Alza (now a Johnson & Johnson company).
Alain Baron, MD
Dr. Baron is founding CEO of Elcelyx. He is also a clinical advisor to Essentialis. Prior to founding Elcelyx, he was Senior Vice President for Research at Amylin Pharmaceutical. He had previously served in various senior clinical roles at Amylin. Prior to Amylin Pharmaceutical, Dr. Baron was Professor of Medicine and Director of the Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine.